U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07032727) titled 'Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations' on June 16.
Brief Summary: To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.
Study Start Date: Dec. 03, 2025
Study Type: INTERVENTIONAL
Condition:
Targeted Therapy
IDH1-Mutated Malignancies
Mutations
Intervention:
DRUG: Olutasidenib
Given by po
DRUG: Cladribine (CLAD)
Given by IV
DRUG: Venetoclax
Given by po
DRUG: Gilteritinib
Given by po
DRUG: R...